vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.

Idaho Strategic Resources, Inc. is the larger business by last-quarter revenue ($14.6M vs $8.1M, roughly 1.8× Arcellx, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -766.0%, a 830.3% gap on every dollar of revenue. On growth, Idaho Strategic Resources, Inc. posted the faster year-over-year revenue change (92.0% vs -79.3%). Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $-63.9M). Over the past eight quarters, Idaho Strategic Resources, Inc.'s revenue compounded faster (57.2% CAGR vs -24.6%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

ACLX vs IDR — Head-to-Head

Bigger by revenue
IDR
IDR
1.8× larger
IDR
$14.6M
$8.1M
ACLX
Growing faster (revenue YoY)
IDR
IDR
+171.3% gap
IDR
92.0%
-79.3%
ACLX
Higher net margin
IDR
IDR
830.3% more per $
IDR
64.3%
-766.0%
ACLX
More free cash flow
IDR
IDR
$72.1M more FCF
IDR
$8.2M
$-63.9M
ACLX
Faster 2-yr revenue CAGR
IDR
IDR
Annualised
IDR
57.2%
-24.6%
ACLX

Income Statement — Q1 FY2025 vs Q4 FY2025

Metric
ACLX
ACLX
IDR
IDR
Revenue
$8.1M
$14.6M
Net Profit
$-62.3M
$9.4M
Gross Margin
68.5%
Operating Margin
-847.6%
62.4%
Net Margin
-766.0%
64.3%
Revenue YoY
-79.3%
92.0%
Net Profit YoY
-765.1%
220.6%
EPS (diluted)
$-1.13
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
IDR
IDR
Q4 25
$14.6M
Q3 25
$11.1M
Q2 25
$9.5M
Q1 25
$8.1M
$7.3M
Q4 24
$15.3M
$7.6M
Q3 24
$26.0M
$6.2M
Q2 24
$27.4M
$6.1M
Q1 24
$39.3M
$5.9M
Net Profit
ACLX
ACLX
IDR
IDR
Q4 25
$9.4M
Q3 25
$3.0M
Q2 25
$2.8M
Q1 25
$-62.3M
$1.6M
Q4 24
$-47.1M
$2.9M
Q3 24
$-25.9M
$1.6M
Q2 24
$-27.2M
$2.2M
Q1 24
$-7.2M
$2.2M
Gross Margin
ACLX
ACLX
IDR
IDR
Q4 25
68.5%
Q3 25
63.6%
Q2 25
57.8%
Q1 25
50.8%
Q4 24
53.3%
Q3 24
48.7%
Q2 24
50.2%
Q1 24
48.1%
Operating Margin
ACLX
ACLX
IDR
IDR
Q4 25
62.4%
Q3 25
23.4%
Q2 25
26.6%
Q1 25
-847.6%
19.3%
Q4 24
-348.2%
36.2%
Q3 24
-129.1%
23.4%
Q2 24
-127.8%
34.2%
Q1 24
-40.3%
36.3%
Net Margin
ACLX
ACLX
IDR
IDR
Q4 25
64.3%
Q3 25
26.8%
Q2 25
29.2%
Q1 25
-766.0%
22.1%
Q4 24
-308.4%
38.5%
Q3 24
-99.4%
25.8%
Q2 24
-99.3%
35.2%
Q1 24
-18.3%
36.8%
EPS (diluted)
ACLX
ACLX
IDR
IDR
Q4 25
$0.62
Q3 25
$0.20
Q2 25
$0.20
Q1 25
$-1.13
$0.12
Q4 24
$-0.87
$0.21
Q3 24
$-0.48
$0.12
Q2 24
$-0.51
$0.17
Q1 24
$-0.14
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
IDR
IDR
Cash + ST InvestmentsLiquidity on hand
$543.3M
Total DebtLower is stronger
$2.3M
Stockholders' EquityBook value
$416.9M
$108.2M
Total Assets
$648.1M
$116.2M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
IDR
IDR
Q4 25
Q3 25
Q2 25
Q1 25
$543.3M
Q4 24
$587.4M
Q3 24
$574.3M
Q2 24
$516.7M
$6.3M
Q1 24
$573.9M
$5.3M
Total Debt
ACLX
ACLX
IDR
IDR
Q4 25
$2.3M
Q3 25
$3.0M
Q2 25
$3.3M
Q1 25
$3.7M
Q4 24
$1.7M
Q3 24
$2.9M
Q2 24
$2.7M
Q1 24
$3.3M
Stockholders' Equity
ACLX
ACLX
IDR
IDR
Q4 25
$108.2M
Q3 25
$74.3M
Q2 25
$49.3M
Q1 25
$416.9M
$39.8M
Q4 24
$454.8M
$37.7M
Q3 24
$483.0M
$33.1M
Q2 24
$487.2M
$25.4M
Q1 24
$496.6M
$21.6M
Total Assets
ACLX
ACLX
IDR
IDR
Q4 25
$116.2M
Q3 25
$83.1M
Q2 25
$57.7M
Q1 25
$648.1M
$48.1M
Q4 24
$711.3M
$44.0M
Q3 24
$764.9M
$40.8M
Q2 24
$734.3M
$32.2M
Q1 24
$779.7M
$28.7M
Debt / Equity
ACLX
ACLX
IDR
IDR
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
Q2 24
0.11×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
IDR
IDR
Operating Cash FlowLast quarter
$-63.1M
$10.7M
Free Cash FlowOCF − Capex
$-63.9M
$8.2M
FCF MarginFCF / Revenue
-786.4%
56.0%
Capex IntensityCapex / Revenue
9.6%
17.7%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$-122.5M
$12.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
IDR
IDR
Q4 25
$10.7M
Q3 25
$2.4M
Q2 25
$3.5M
Q1 25
$-63.1M
$2.4M
Q4 24
$-46.0M
$3.2M
Q3 24
$30.7M
$2.5M
Q2 24
$-36.2M
$2.6M
Q1 24
$-31.9M
$2.6M
Free Cash Flow
ACLX
ACLX
IDR
IDR
Q4 25
$8.2M
Q3 25
$709.8K
Q2 25
$2.5M
Q1 25
$-63.9M
$1.0M
Q4 24
$-47.5M
$2.1M
Q3 24
$28.4M
$1.9M
Q2 24
$-39.5M
$2.4M
Q1 24
$-38.3M
$2.3M
FCF Margin
ACLX
ACLX
IDR
IDR
Q4 25
56.0%
Q3 25
6.4%
Q2 25
26.5%
Q1 25
-786.4%
13.8%
Q4 24
-311.3%
28.0%
Q3 24
109.2%
30.4%
Q2 24
-144.1%
38.7%
Q1 24
-97.7%
38.3%
Capex Intensity
ACLX
ACLX
IDR
IDR
Q4 25
17.7%
Q3 25
15.3%
Q2 25
10.8%
Q1 25
9.6%
19.4%
Q4 24
9.8%
13.6%
Q3 24
8.8%
9.8%
Q2 24
11.7%
4.3%
Q1 24
16.4%
5.5%
Cash Conversion
ACLX
ACLX
IDR
IDR
Q4 25
1.15×
Q3 25
0.81×
Q2 25
1.28×
Q1 25
1.50×
Q4 24
1.08×
Q3 24
1.56×
Q2 24
1.22×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons